Safety and Efficiency of γδ T Cell Against Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03180437|
Recruitment Status : Completed
First Posted : June 8, 2017
Last Update Posted : September 12, 2019
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Procedure: Cryosurgery or IRE surgery Biological: γδ T cell Other: γδ T cells/ A Cryosurgery or IRE||Phase 1 Phase 2|
Pancreatic tumor will be removed using tumor reducing surgery such as cryosurgery.
PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||γδ T Cell Immunotherapy for Treatment of Pancreatic Cancer|
|Actual Study Start Date :||June 15, 2017|
|Actual Primary Completion Date :||June 15, 2018|
|Actual Study Completion Date :||June 15, 2019|
Experimental: Group A
In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
Procedure: Cryosurgery or IRE surgery
Cryosurgery or IRE surgery will be used in local tumor
Experimental: Group B
In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Biological: γδ T cell
γδ T cells will be used against Pancreatic Cancer
Experimental: Group C
In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
Other: γδ T cells/ A Cryosurgery or IRE
Combination γδ T cell and Cryosurgery or IRE surgery will be used in Pancreatic Cancer
- Relief degree of tumors [ Time Frame: 3 months ]It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
- Progress free survival（PFS） [ Time Frame: 1 year ]
- Overall survival（OS） [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180437
|Biotherapy center in Fuda cancer hospital|
|Guangzhou, Guangdong, China, 510665|
|Principal Investigator:||Jibing Chen, PhD||Biological treatment center in Fuda cancer hospital Guangzhou, Guangdong, China, 510000|